EP Patent

EP1845097A1 — Oxadiazole derivatives as COMT inhibitors

Assigned to Bial Portela and Cia SA · Expires 2007-10-17 · 19y expired

What this patent protects

This invention relates to novel substituted [1,2,4]-oxadiazoles, their use in the treatment of some central and peripheral nervous system disorders, methods for their preparation and pharmaceutical compositions containing them.

USPTO Abstract

This invention relates to novel substituted [1,2,4]-oxadiazoles, their use in the treatment of some central and peripheral nervous system disorders, methods for their preparation and pharmaceutical compositions containing them.

Drugs covered by this patent

Patent Metadata

Patent number: EP1845097A1
Jurisdiction: EP
Classification: —
Expires: 2007-10-17
Drug substance claim: No
Drug product claim: No
Assignee: Bial Portela and Cia SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.